Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BBNX NASDAQ:SIBN NYSEAMERICAN:STXS OTCMKTS:WEDXF On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBBNXBeta Bionics$14.74-2.3%$15.77$8.89▼$24.50$640.75MN/A609,204 shs488,823 shsSIBNSiBone$15.68-3.9%$17.68$11.70▼$20.05$676.45M0.91455,122 shs371,646 shsSTXSStereotaxis$2.50+14.2%$2.25$1.54▼$2.72$215M1.51697,203 shs1.12 million shsWEDXFWestaim$20.61-0.2%$22.41$16.62▼$25.98$691.57M0.233,818 shs10,086 shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBBNXBeta Bionics0.00%-10.12%+8.70%+6.89%+1,473,999,900.00%SIBNSiBone0.00%-9.83%-16.51%-15.29%+11.05%STXSStereotaxis0.00%+12.61%+11.61%+17.37%+38.89%WEDXFWestaim0.00%-4.72%-8.36%-13.00%+615.63%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBBNXBeta Bionics2.4955 of 5 stars4.40.00.00.02.40.80.0SIBNSiBone4.0472 of 5 stars3.53.00.03.31.92.50.6STXSStereotaxis0.1981 of 5 stars0.00.00.00.01.91.70.6WEDXFWestaim0.6156 of 5 stars0.03.00.00.02.80.00.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBBNXBeta Bionics 2.75Moderate Buy$22.5653.02% UpsideSIBNSiBone 3.00Buy$23.6750.94% UpsideSTXSStereotaxis 0.00N/AN/AN/AWEDXFWestaim 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest STXS, WEDXF, BBNX, and SIBN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/5/2025SIBNSiBoneCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$25.007/30/2025BBNXBeta BionicsTruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$18.00 ➝ $21.007/30/2025BBNXBeta BionicsRobert W. BairdSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price TargetNeutral ➝ Neutral$15.00 ➝ $17.006/16/2025BBNXBeta BionicsTruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$26.006/12/2025BBNXBeta BionicsLake Street CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy ➝ Buy$30.005/30/2025BBNXBeta BionicsThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageNeutral$16.005/30/2025BBNXBeta BionicsWolfe ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$20.00(Data available from 8/10/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBBNXBeta Bionics$65.12M9.84N/AN/A$6.94 per share2.12SIBNSiBone$167.18M4.05N/AN/A$3.95 per share3.97STXSStereotaxis$26.92M7.99N/AN/A$0.07 per share35.71WEDXFWestaim$17.04M40.59N/AN/A$23.28 per share0.89Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBBNXBeta Bionics-$54.76MN/A0.00∞N/AN/AN/AN/AN/ASIBNSiBone-$30.91M-$0.56N/AN/AN/A-12.83%-14.20%-10.38%N/ASTXSStereotaxis-$24.05M-$0.28N/AN/AN/A-73.43%-354.30%-48.87%N/AWEDXFWestaim-$16.18M-$2.17N/A∞N/A-253.76%-9.36%-8.82%8/12/2025 (Estimated)Latest STXS, WEDXF, BBNX, and SIBN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/4/2025Q2 2025SIBNSiBone-$0.19-$0.14+$0.05-$0.14$48.12 million$48.63 million7/29/2025Q2 2025BBNXBeta Bionics-$0.51-$0.39+$0.12-$0.39$19.73 million$23.24 million5/14/2025Q1 2025WEDXFWestaim-$0.0316-$0.34-$0.3084-$0.34$1.34 million($4.70) millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBBNXBeta BionicsN/AN/AN/AN/AN/ASIBNSiBoneN/AN/AN/AN/AN/ASTXSStereotaxisN/AN/AN/AN/AN/AWEDXFWestaimN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBBNXBeta BionicsN/A14.6813.79SIBNSiBone0.218.387.26STXSStereotaxisN/A1.070.66WEDXFWestaimN/A11.4011.40Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBBNXBeta BionicsN/ASIBNSiBone98.11%STXSStereotaxis45.35%WEDXFWestaimN/AInsider OwnershipCompanyInsider OwnershipBBNXBeta BionicsN/ASIBNSiBone4.00%STXSStereotaxis17.77%WEDXFWestaim4.21%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBBNXBeta Bionics29443.47 millionN/AN/ASIBNSiBone35043.14 million41.42 millionOptionableSTXSStereotaxis13086.00 million70.72 millionNot OptionableWEDXFWestaim733.56 million32.14 millionNot OptionableSTXS, WEDXF, BBNX, and SIBN HeadlinesRecent News About These CompaniesWestaim (OTCMKTS:WEDXF) Sees Large Volume Increase - Should You Buy?August 9 at 1:00 PM | marketbeat.comWestaim (OTCMKTS:WEDXF) Shares Down 0.9% - Here's What HappenedAugust 5, 2025 | marketbeat.comWestaim (OTCMKTS:WEDXF) Sees Large Volume Increase - What's Next?July 21, 2025 | marketbeat.comAM Best Assigns Credit Ratings to Ceres Life Insurance CompanyJuly 15, 2025 | businesswire.comThe Westaim Corporation Reports Q1 2025 ResultsMay 14, 2025 | businesswire.comCC Capital and Westaim Complete Transaction, Creating Integrated Insurance and Asset Management PlatformApril 3, 2025 | businesswire.comWestaim Announces Receipt of Required Regulatory Approvals in Connection with CC Capital TransactionMarch 27, 2025 | businesswire.comThe Westaim Corporation Announces Normal Course Issuer BidMarch 26, 2025 | businesswire.comThe Westaim Corporation Reports Q4 and Full Year 2024 Results and Update on Timing of Proposed Transactions with CC CapitalMarch 26, 2025 | businesswire.comWestaim completes acquisition of ManhattanLifeFebruary 6, 2025 | insurancebusinessmag.comIWestaim: Transforming Into A Potential Long-Term Compounding MachineJanuary 30, 2025 | seekingalpha.comThe Westaim Corp WEDXDJanuary 14, 2025 | morningstar.comMThe Westaim Corporation Announces Completion of ArrangementJanuary 2, 2025 | businesswire.comWestaim: Stocks Undervalued by Analyst Consensus on TSX-V (WED)December 22, 2024 | theglobeandmail.comThe Westaim Corporation appoints CRODecember 6, 2024 | complianceweek.comCThe Westaim Corporation Files Management Information Circular for Special Shareholders Meeting and Encourages Shareholders to Access Meeting Materials OnlineNovember 27, 2024 | newsfilecorp.comNThe Westaim Corporation Files Management Information Circular for Special Shareholders Meeting and Encourages Shareholders to Access Meeting Materials OnlineNovember 27, 2024 | newsfilecorp.comNCC Capital & Westaim partner on new integrated insurance and asset management platformOctober 11, 2024 | reinsurancene.wsRCC Capital and Westaim to create insurance and asset management platformOctober 9, 2024 | pehub.comWestaim Corporation: A Bargain In The Asset Management WorldSeptember 4, 2024 | seekingalpha.comWestaim Corporation: Still Undervalued Based On NAVJuly 19, 2024 | seekingalpha.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeSTXS, WEDXF, BBNX, and SIBN Company DescriptionsBeta Bionics NASDAQ:BBNX$14.74 -0.35 (-2.32%) As of 08/8/2025 04:00 PM EasternBeta Bionics, Inc. is a commercial-stage medical device company. It engages in the design, development, and commercialization of solutions for insulin-requiring people with diabetes. The company was founded by Edward R. Damiano on October 21, 2015 and is headquartered in Irvine, CA.SiBone NASDAQ:SIBN$15.68 -0.64 (-3.92%) Closing price 08/8/2025 04:00 PM EasternExtended Trading$15.70 +0.02 (+0.13%) As of 08/8/2025 05:06 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.SI-BONE, Inc., a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products. The company also provides iFuse-3D, a titanium implant that combines the triangular cross-section of the iFuse implant with the proprietary 3D-printed porous surface and fenestrated design; iFuse-TORQ, a set of 3D-printed threaded implants designed to treat pelvic trauma; and iFuse Bedrock Granite implant provides sacroiliac fusion and sacropelvic fixation as a foundational element for segmental spinal fusion. It markets its products primarily with a direct sales force, as well as through agents and resellers. SI-BONE, Inc. was incorporated in 2008 and is headquartered in Santa Clara, California.Stereotaxis NYSEAMERICAN:STXS$2.50 +0.31 (+14.16%) Closing price 08/8/2025 04:10 PM EasternExtended Trading$2.49 -0.01 (-0.40%) As of 08/8/2025 07:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Stereotaxis, Inc. designs, manufactures, and markets robotic systems, instruments, and information systems for the interventional laboratory in the United States and internationally. Its robotic magnetic navigation (RMN) systems include the Genesis RMN and Niobe systems, which enable physicians to complete complex interventional procedures by providing image-guided delivery of catheters and guidewires through the blood vessels and chambers of the heart to treatment sites. The company provides Odyssey, a real-time information solution to manage, control, record, and share procedures across networks; and Stereotaxis Imaging Model S X-ray system, a single-plane, full-power x-ray system, including c-arm, powered table, motorized boom, and monitors for a robotic interventional operating room. In addition, it offers disposables and other accessories, such as QuikCAS automated catheter advancement disposables for the remote advancement of electrophysiology catheters. Further, the company provides Vdrive, a system that offers navigation and stability for the diagnostic and therapeutic devices designed to improve interventional procedures; and V-Loop, V-Sono, and V-CAS disposable components. It markets its products through direct sales force, distributors, and sales agents. The company has a strategic collaboration with MAGiC catheter for cardiac ablation procedures. Stereotaxis, Inc. was incorporated in 1990 and is based in Saint Louis, Missouri.Westaim OTCMKTS:WEDXF$20.61 -0.04 (-0.19%) As of 08/8/2025 02:38 PM EasternThe Westaim Corporation is a private equity firm specializing in direct and indirect investments through acquisitions, joint ventures, secondary investments both direct and indirect, fund of fund investments, and other arrangements. For direct investments, the firm invests in early venture, mid venture, late venture, middle market, later stage, mature, emerging growth, PIPEs, and buyout transactions. For fund of fund investments, it seeks to invest in private equity funds, venture capital funds, and hedge funds. The firm seeks to provide long term capital to businesses operating in the global financial services industry. It typically acquires controlling interests in businesses. The firm seeks to acquire debt, equity, or derivative securities of both public and private companies. It invests with the objective of providing its shareholders with capital appreciation and real wealth preservation. The firm seeks to provide its portfolio companies with advisory services including, but not limited to, advice on capital allocation, financing strategy, performance measurement and merger and acquisition support. It also seeks to partner with like-minded providers of third party capital to help supplement the firm's own capital, when completing acquisitions. The firm generally seeks to hold its investments for seven to 15 years. The Westaim Corporation was founded in 1996 and is based in Toronto, Canada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 08/04 - 08/08 Rocket Lab Reports Q2 Results: Is the Bull Thesis Still Intact? Airbnb Beats Earnings, But the Growth Story Is Losing Altitude Dutch Bros Just Flipped the Script With a Massive Earnings Beat Amazon Takes an Equity Stake in IonQ—Any Upside Potential? D-Wave Delivers Growth Shock—Investors Eye Quantum Future Is Eli Lilly’s 14% Post-Earnings Slide a Buy-the-Dip Opportunity? Constellation Energy’s Earnings Beat Signals a New Era Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
